1

OraSure Technologies

#8160

Rank

$224.4M

Marketcap

US United States

Country

OraSure Technologies
Leadership team

Mr. Scott Gleason (Sr. VP of Investor Relations & Corp. Communications)

Ms. Kathleen Gallagher Weber (Chief Product Officer)

Ms. Carrie Eglinton Manner (Pres, CEO & Director)

Products/ Services
Biotechnology, Health Care, Industrial, Medical
Number of Employees
500 - 1000
Headquarters
Bethlehem, Pennsylvania, United States
Established
1987
Company Registration
SEC CIK number: 0001116463
Revenue
100M - 500M
Traded as
OSUR
Social Media
Overview
Location
Summary
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
History

OraSure was founded in 1988 by Sam Niedbala, Mike Gausling and two others as SolarCare Technologies Corp.In 2000, the company merged with Epitope, a company that had developed a way of testing for HIV. After the merger, the company became OraSure.In 2004, founder Sam Niedbala retired from the company.In response to the COVID-19 pandemic, OraSure expanded the company by creating over 150 jobs in Bethlehem to work on creating a rapid, at-home coronavirus test. The company had previously developed products to rapidly check for Hepatitis C and Ebola.

Products

OraSure created the OraQuick test, which can detect the presence of HIV from a mouth swab within 20 minutes. In 2004, the company began marketing OraQuick to health care practitioners.In a trial by OraSure, the test correctly detected HIV in those carrying the disease 93 percent of the time, a rate below the FDA-recommended 95 percent threshold for accuracy. The test was more accurate at clearing patients who didn't have the disease, correctly identifying HIV-negative users 99 percent of the time.In July 2012, OraQuick was approved by the Food and Drug Administration for over-the-counter use.

Mission
Our mission is to develop and deliver innovative, differentiated products and services that empower healthcare professionals to advance molecular diagnostics, improve patient access to care, and enhance overall health and wellness.
Vision
To be a global leader in sample collection, infectious disease testing, and consumer health through innovative products for professional and consumer use.
Key Team

Mr. Kenneth J. McGrath (Chief Financial Officer)

Ms. Trace Custer (Sr. VP of Quality & Regulatory)

Ms. Michele Marie Miller (Sr. VP, Chief Accounting Officer, Controller & Assistant Sec.)

Mr. Stefano Taucer (Gen. Counsel & Corp. Sec.)

Mr. David A. Rappaport C.F.A., CFA (Sr. VP Corp. Devel., Strategy & Integration)

Amy Steigerwalt (Sr. VP of HR)

Mr. Zachary Wert (Sr. VP of Global Operations)

Recognition and Awards
OraSure Technologies has been recognized for its groundbreaking products, winning numerous awards over the years, including the 2017 Global Exhibition on Development of Medical Innovation, the 2017 Frost & Sullivan Award for Technology Innovation, and the 2014 U.S. Food and Drug Administration Medical Device Award.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

OraSure Technologies
Leadership team

Mr. Scott Gleason (Sr. VP of Investor Relations & Corp. Communications)

Ms. Kathleen Gallagher Weber (Chief Product Officer)

Ms. Carrie Eglinton Manner (Pres, CEO & Director)

Products/ Services
Biotechnology, Health Care, Industrial, Medical
Number of Employees
500 - 1000
Headquarters
Bethlehem, Pennsylvania, United States
Established
1987
Company Registration
SEC CIK number: 0001116463
Revenue
100M - 500M
Traded as
OSUR
Social Media